<div id="readability-page-1"><p>Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Athira Pharma yesterday and set a price target of $4.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Suvannavejh is a 5-star analyst with an average return of <span>16.6%</span> and a 49.90% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Insmed, and EyePoint Pharmaceuticals.</p> <p>The word on The Street in general, suggests a Hold analyst consensus rating for Athira Pharma with a $4.00 average price target.</p></div>

ATHA

<p>Mizuho Securities analyst Graig Suvannavejh maintains a Hold rating for Athira Pharma with a $4.00 price target. Suvannavejh, a 5-star analyst with a 16.6% average return, covers the Healthcare sector. The consensus among analysts is a Hold rating for Athira Pharma, with a $4.00 average price target.</p>

Mizuho Securities Sticks to Their Hold Rating for Athira Pharma (ATHA)